AR047732A1 - Nitrooxiderivados de drogas antihipertensivas - Google Patents

Nitrooxiderivados de drogas antihipertensivas

Info

Publication number
AR047732A1
AR047732A1 ARP040104485A ARP040104485A AR047732A1 AR 047732 A1 AR047732 A1 AR 047732A1 AR P040104485 A ARP040104485 A AR P040104485A AR P040104485 A ARP040104485 A AR P040104485A AR 047732 A1 AR047732 A1 AR 047732A1
Authority
AR
Argentina
Prior art keywords
group
integer
formula
ono2
formulas
Prior art date
Application number
ARP040104485A
Other languages
English (en)
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of AR047732A1 publication Critical patent/AR047732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nitooxiderivados de bloqueadores b-adrenérgicos y enantiomeros y diastereoisomeros y sus sales aceptables para uso farmacéutico de los mismos. Composiciones farmacéuticas que los contienen y su uso para el tratamiento de hipertension, enfermedades cardiovasculares, glaucoma, migrana y enfermedades vasculares. Reivindicacion 1: Un compuesto caracterizado porque es de formula general A-(Y-ONO2)s (1) y los enantiomeros, diastereoisomeros y sales aceptables para uso farmacéutico del mismo donde: s es un entero igual a 1 o 2; A se selecciona ente los siguientes residuos bloqueadores beta-adrenérgicos de formula (2), donde R1 se selecciona entre el grupo que comprende: las formulas (2a) a (2i) y (2l) a (2n); R2 se selecciona entre el grupo que comprende: -CH(CH2)2, -C(CH3)3 o las formulas 3a y 3b cuando el radical R1 se selecciona entre las formulas (2a), (2c), (2d), (2g), (2h), (2i), (2m), R2 es -CH(CH3)2; cuando el radical R1 se selecciona entre las formulas (2e), (2f) o (2n), R2 es -C(CH3)3; cuando R1 es el radical (2b), R2 es (3a); cuando R1 es el radical (2l), R2 es (3b); Z es H o es u grupo capaz de unirse a Y seleccionado entre el grupo que comprende -C(O)-, -C(O)O- o como se muestra en la formula (4) donde R??y Rö son iguales o distintos, y son H o C1-4 alquilo lineal o ramificado; Z1 es H o un grupo -C(O)- capaz de unirse a Y; con la condicion de que cuando s de formula (1) es 1, Z o Z1 es H; Y es un radical bivalente con el siguiente significado: a) -C1-20 alquileno lineal o ramificado que está opcionalmente sustituido con uno más de los sustituyentes seleccionados entre el grupo que comprende: átomos de halogeno, hidroxi, -ONO2 o T es -OC(O)(C1-10 alquil)-ONO2, -O(C1-10 alquil)-ONO2; b) cicloalquileno con entre 5 y 7 átomos de C en el anillo cicloalquileno, donde el anillo está opcionalmente sustituido con cadenas laterales T1, donde T1 es alquilo lineal o ramificado con entre 1 y 10 átomos de C; c) formula (5) donde: n es un entero entre 0 y 20 y n1 es un entero entre 1 y 20; n2, n3, n4 y n5 son enteros iguales o distintos entre sí, igual a 0 o 1; R3 y R4 se seleccionan en forma independiente entre H o CH3; Y1 es -CH2- o -(CH2)na-CH= CH- donde na es un entero entre 0 y 20; X1 es -WC(O)- o -C(O)W-, donde W es O, S o NH; d) formula (6) donde: n1 y X1 son como se ha definido; n6 es un entero entre 1 uy 20 y n7 es un entero entre 0 y 20, R5 y R5?? R6 y R6?? se selecc ionan en forma independiente entre el grupo que comprende H, CH3, OH, NH2, NHCOCH3, COOH, CH2SH y C(CH3)2SH; cuando el enlace entre los C CA Y CB es un doble enlace R5 y R6 o R6?? y R5?? están ausentes; con la condicion de que cuando Y se selecciona entre los radicales bivalentes mencionados en c)- d), el grupo -ONO2 está unido al grupo -(CH2)n1-; e)formula (7) y formula (8) donde X2 es O o S, n10a, n10 y n12 son enteros seleccionados en forma independiente entre 0 y 20, n11 es un entero entre 0 y 6; R11 es H, CH3 o nitrooxi; R11a es CH3 o grupo nitrooxi; f) formula (9) donde n8 es un entero entre 0 y 10; n9 es un entero entre 1 y 10; R9, R10, R8, R7 son iguales o distintos, y son H o C1-4 alquilo lineal o ramificado; donde el grupo -ONO2 está unido a =[C]-n9 donde n9 es como se ha definido Y2 es un anillo heterocíclico saturado, insaturado o aromático de 5 o 6 miembros, con uno o más heteroátomos seleccionados entre N, O, S, y se selecciona entre el grupo que comprende: las formulas (Y1) a (Y13).
ARP040104485A 2003-12-02 2004-12-01 Nitrooxiderivados de drogas antihipertensivas AR047732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03104484 2003-12-02

Publications (1)

Publication Number Publication Date
AR047732A1 true AR047732A1 (es) 2006-02-15

Family

ID=34639309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104485A AR047732A1 (es) 2003-12-02 2004-12-01 Nitrooxiderivados de drogas antihipertensivas

Country Status (22)

Country Link
US (1) US7825263B2 (es)
EP (1) EP1691804B1 (es)
JP (1) JP2007513114A (es)
KR (1) KR20060120677A (es)
CN (1) CN1886132A (es)
AR (1) AR047732A1 (es)
AT (1) ATE358478T1 (es)
AU (1) AU2004294297A1 (es)
BR (1) BRPI0416584A (es)
CA (1) CA2548129A1 (es)
DE (1) DE602004005748T2 (es)
DK (1) DK1691804T3 (es)
ES (1) ES2285549T3 (es)
HR (1) HRP20070283T3 (es)
IL (1) IL174959A0 (es)
NO (1) NO20063057L (es)
PL (2) PL380065A1 (es)
PT (1) PT1691804E (es)
RU (1) RU2006119528A (es)
SI (1) SI1691804T1 (es)
WO (1) WO2005053685A1 (es)
ZA (1) ZA200604458B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233140D1 (de) 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
WO2007090733A1 (en) * 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy derivatives suitable as alpha2 adrenergic receptor agonists
WO2007090793A1 (en) * 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
EP2160192B1 (en) 2007-05-14 2018-03-28 Covidien LP Antimicrobial materials and coatings
US8062653B2 (en) * 2009-02-18 2011-11-22 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
EP3589327A4 (en) * 2017-03-03 2022-04-06 Synovo GmbH NOVEL ANTI-INFECTION AND ANTI-INFLAMMATORY COMPOUNDS
CN115246774A (zh) * 2021-04-27 2022-10-28 南昌弘益科技有限公司 一类新型双羰基类阿魏酸衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2805404A1 (de) * 1978-02-09 1979-08-16 Merck Patent Gmbh 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung
DE3443998A1 (de) 1984-12-01 1986-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim Amino-propanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
DE3512627A1 (de) 1985-04-06 1986-10-09 Boehringer Mannheim Gmbh, 6800 Mannheim Amino-propanol-derivate, verfahren zu deren herstellung, verwendung derselben und diese enthaltende arzneimittel
ES2065291B1 (es) 1993-07-30 1995-10-01 Prodesfarma Sa "nitrato esteres de 1-ariloxi-3-alquilamino-2-propanoles, utilizacion y composicion farmaceutica correspondiente"
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
IT1311923B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
JP2004529204A (ja) * 2001-05-28 2004-09-24 ケムテック、リサーチ、インコーポレーション 新規なアルカロイド誘導体及びこれを含有する医薬組成物
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi

Also Published As

Publication number Publication date
RU2006119528A (ru) 2008-01-10
ZA200604458B (en) 2007-04-25
IL174959A0 (en) 2006-08-20
CN1886132A (zh) 2006-12-27
US20070072854A1 (en) 2007-03-29
SI1691804T1 (sl) 2007-10-31
ES2285549T3 (es) 2007-11-16
DE602004005748T2 (de) 2007-12-27
EP1691804B1 (en) 2007-04-04
PL380065A1 (pl) 2006-12-11
EP1691804A1 (en) 2006-08-23
PL1691804T3 (pl) 2007-08-31
AU2004294297A1 (en) 2005-06-16
US7825263B2 (en) 2010-11-02
CA2548129A1 (en) 2005-06-16
ATE358478T1 (de) 2007-04-15
WO2005053685A1 (en) 2005-06-16
KR20060120677A (ko) 2006-11-27
JP2007513114A (ja) 2007-05-24
NO20063057L (no) 2006-06-30
DK1691804T3 (da) 2007-07-16
HRP20070283T3 (en) 2007-11-30
PT1691804E (pt) 2007-07-04
DE602004005748D1 (de) 2007-05-16
BRPI0416584A (pt) 2007-01-30

Similar Documents

Publication Publication Date Title
AR047081A1 (es) Derivados de prostaglandinas, metodos para su preparacion, composiciones farmaceuticas que las contienen y su uso en el tratamiento del glaucoma y de la hipertension ocular.
AR047732A1 (es) Nitrooxiderivados de drogas antihipertensivas
AR044561A1 (es) Derivados de estatina
AR042397A1 (es) Compuestos de pirazol utiles como inhibidores de proteinquinasa
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR069326A1 (es) Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia.
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
AR057414A1 (es) Derivados de prostaglandina
AR056763A1 (es) Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
AR053330A1 (es) Derivados de nitroxi sartan como bloqueantes del receptor de angiotesina ii
CR7069A (es) Derivados de pirazol para el tratamiento de vih
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CY1104991T1 (el) Ετεροκυκλικες ενωσεις για χρηση στην αγωγη διαταραχων της ουροποιητικης οδου
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
CR6643A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CO6220840A2 (es) Formulaciones para el tratamiento de cancer
AR052328A1 (es) Derivados de 2 - alcoxi - 3, 4, 5 - trihidroxi - alquilamidas, composiciones farmaceuticas que las contienen, y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
ES2179919T3 (es) Nuevos derivados de 2-naftamidas y sus aplicaciones terapeuticas como agonistas de los receptores d3.
AR061598A1 (es) Nitroderivados heterociclicos como antagonistas de receptor de endotelina
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
PE20240928A1 (es) Derivados de triazina y su uso en el tratamiento del cancer
AR031196A1 (es) Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
DK2094650T3 (da) Anvendelse af campholenderivater som duftstofingredienser i parfume og smagsstoffer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal